<i id='77295A8C8B'><strike id='77295A8C8B'><tt id='77295A8C8B'><pre id='77295A8C8B'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Moonlake's readout produced a cash windfall. Risks remain 
Astronauts get first look at the spacecraft that will fly them around the moon 
Wildfire smoke exposes gaps in outdoor worker protections 
Why you get paid to donate plasma but not blood 
Continuity nursing helped my family in our darkest PICU moments 
US soldier in North Korean custody after crossing DMZ line 
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures 
In age of alternative facts, a scholarly course on calling out crap 
Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene
Moonlake's readout produced a cash windfall. Risks remain 
Sage's campaign to raise awareness of postpartum depression hits a nerve 
How to save PrEP access — and even expand it 
Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024 
Sports medicine is finally prioritizing gender equality 
